This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CombiMatrix Corporation Awarded $488,958 Grant Under IRS Section 48D For Qualifying Therapeutic Discovery Projects

IRVINE, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects. All of this grant is available for reimbursement this month, and is for activities incurred for the following projects:

  • Array Comparative Genomic Hybridization, or "aCGH"; and
  • Comprehensive Cancer Array, or "CCA".

"This award comes at an opportune time and will help further advance the development of our molecular diagnostic tests in the fields of early childhood developmental disorders as well as cancer," stated R. Judd Jessup, President and CEO of CombiMatrix Corporation. "We are pleased to have been awarded the full available amount for our projects for which we applied," concluded Mr. Jessup.

By using funds provided from the Patient Protection and Affordable Care Act (ACA) passed earlier this year, the Internal Revenue Service has awarded $1 billion in grants and tax credits to a large number of small biomedical and molecular diagnostic companies, including CombiMatrix. In order to have qualified for an award, businesses with fewer than 250 employees were required to submit applications earlier this year for individual research and development projects that showed, among other requirements, the potential to (i) result in new therapies to treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases or conditions; (ii) reduce long-term health care costs in the United States; or (iii) significantly advance the goal of curing cancer within 30 years. For additional information about IRS Section 48D, please visit http://www.irs.gov/irb/2010-23_IRB/ar08.html#doe1444 .

ABOUT COMBIMATRIX CORPORATION

CombiMatrix Corporation is a diversified molecular diagnostics company that primarily operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Diagnostics, Inc. ("CMDX"). CMDX operates as a diagnostics reference laboratory that provides genetic and other diagnostics services to physicians, hospitals and clinics . Additional information about CombiMatrix Corporation is available at www.combimatrix.com . Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624 .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions.  Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACT:  CombiMatrix Corporation
          R. Judd Jessup, President & CEO
          (949) 753-0624
          Fax (949) 753-1504

CombiMatrix Corporation

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs